Prevention of Chronic Rejection of Marginal Kidney Graft by Using a Hydrogen Gas-Containing Preservation Solution and Adequate Immunosuppression in a Miniature Pig Model.
Kotaro Nishi, Satomi Iwai, Kazuki Tajima, Shozo Okano, Motoaki Sano, Eiji Kobayashi · Frontiers in immunology · 2020
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In an animal model, marginal kidney processed by hydrogen gas-containing preservation solution has been engrafted for long-term (longer than 100 days). These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen was evaluated in this publication and summarizes the source-grounded findings below. Marginal kidney processed by hydrogen gas-containing preservation solution has been engrafted for long-term (longer than 100 days).
What the Researchers Studied
The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
The hydrogen addition method to ETK was performed using a hydrogen storage alloy canister as described ( 26 ). The hydrogen was fed from a rubber stopper into a bag of ETK cooled to 4°C and mixed when the internal pressure of the container reached 0.06 ppm. The hydrogen concentration decreased slowly when stored at 4°C under normal pressure, and dissolved hydrogen concentration of 1 ppm or more could be secured for 4 h. Marginal kidney processed by hydrogen gas-containing preservation solution has been engrafted for long-term (longer than 100 days). The authors concluded that marginal kidney graft from donor after cardiac death is an acceptable model for chronic rejection and that if the transplantation is carried out using a strict immunosuppressive protocol, chronic rejection may be alleviated even with the marginal kidney. It was suggested that the hydrogen-dissolved organ preservation solution suppresses the upper cascade of fibrosis by removing hydroxyl radicals, reactive oxygen species, and inflammatory cytokines, and may contribute to the reduction of chronic rejection.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The reported sample size was 4. The study used a preclinical animal experiment.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.